September 23, 2017 |
CardioMEMS Data Shows Pulmonary Artery Pressure Monitoring Significantly Reduces Heart Failure Hospitalizations in Patients with Chronic Kidney Disease
September 15, 2014  | 

St. Paul, MN - St. Jude Medical, a global medical device company, today announced a new data analysis from the CHAMPION clinical trial that evaluated outcomes in a subgroup of patients with renal dysfunction. The CHAMPION trial looked at the safety and effectiveness of the CardioMEMS HF System for patients with New York Heart Association (NYHA) Class III heart failure (HF) who had been hospitalized for HF in the previous 12 months.

The CardioMEMS system uses a miniaturized, wireless monitoring sensor that is implanted in the pulmonary artery (PA) during a minimally invasive procedure to directly measure PA pressure. Measuring PA pressure allows clinicians to proactively manage treatment for patients with worsening HF before visible symptoms, such as weight and blood pressure changes, occur. The system allows patients to transmit PA pressure data from their homes to their health care providers, who then manage appropriate medication changes to reduce the likelihood of hospitalization.

The subgroup data analysis of 297 patients followed for 18 months, presented during the Heart Failure Society of America (HFSA) 18th annual scientific meeting in Las Vegas, looked at the potential benefit for patients with NYHA Class III HF and chronic kidney disease (CKD) using the CardioMEMS system to measure PA pressure without adversely affecting renal function. These data show that management based on PA pressure reduced HF hospitalization in this patient population by 42 percent compared to the control group and did not adversely affect renal function. Continue>

Page | 1 2
Suggested Articles